Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Next Previous
Trial Profile

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TROP2-CAR-NK-Cells (Primary) ; Cyclophosphamide; Fludarabine; Rimiducid
  • Indications HER2 negative breast cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms TROPIKANA

Most Recent Events

  • 27 Nov 2023 Planned primary completion date changed from 30 Apr 2028 to 30 Apr 2038.
  • 24 Oct 2023 Status changed from not yet recruiting to recruiting.
  • 09 Oct 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top